Imagine a world where surgeons can visualize vital structures in real-time, making even the most complex procedures a breeze. Welcome to the era of fluorescence-guided surgery, where UltraGreen.ai is leading the charge. This Singapore-based company has been a pioneering force in the development, manufacturing, and commercialization of indocyanine green (ICG), a sterile injectable dye that illuminates tissue perfusion, vascular structures, biliary anatomy, and tumour margins under near-infrared light.

## The Game-Changer: ICG and Fluorescence-Guided Surgery

UltraGreen.ai’s ICG has become an essential tool in modern surgical practice, with a broad range of applications across oncology, gastrointestinal, hepatobiliary, cardiovascular, plastic reconstructive, and transplant surgery. By providing real-time visual cues, ICG helps surgeons improve precision, accuracy, and patient outcomes. The company’s leadership in this space is a result of over a decade of sustained investment in regulatory approvals, quality systems, clinical partnerships, and global distribution capabilities.

## A Global Reach: UltraGreen.ai’s Regulatory Footprint

UltraGreen.ai’s ICG product is registered in 35 countries and distributed under exemption pathways in another 33 markets, giving it active commercial presence in 68 countries across the Americas, Europe, Middle East & Africa (EMEA), and Asia-Pacific. This extensive reach is a significant competitive barrier, as sterile injectables require extensive documentation, validated manufacturing processes, and GMP-compliant facilities. The company’s operating model relies on third-party manufacturing and distribution partners, with exclusive active pharmaceutical ingredient (API) supply arrangements and an outsourced manufacturing strategy using contract manufacturing organizations (CMOs) with experience in sterile injectables.

## Industry Outlook: Fluorescence-Guided Surgery on the Rise

Fluorescence-guided surgery (FGS) is a surgical technique that uses fluorescent agents, such as ICG, together with near-infrared (NIR) imaging systems to enhance intraoperative visualization. Despite its documented clinical applications, adoption of FGS remains at an early stage globally. Frost & Sullivan estimates indicate that penetration of FGS in the United States is below 25% of eligible procedures, reflecting historical constraints such as limited availability of NIR-compatible imaging systems, uneven surgeon training, and differences in reimbursement practices. However, the Asia-Pacific region is expected to be the fastest-growing market for ICG between 2024 and 2030, with a forecast compound annual growth rate of 16.6%.

## The Future of Surgery: UltraGreen.ai’s Leadership

UltraGreen.ai’s commitment to innovation and excellence has made it a leader in the fluorescence-guided surgery market. The company’s ICG product is used across multiple surgical specialties, including ophthalmology, gastrointestinal surgery, oncologic surgery, plastic and reconstructive surgery, gynaecologic surgery, thoracic surgery, urology, neurosurgery, transplant surgery, and cardiovascular surgery. With a strong presence in 68 countries, UltraGreen.ai is poised to continue driving the adoption of fluorescence-guided surgery and shaping the future of modern medicine.

## Conclusion

UltraGreen.ai’s fluorescence-guided technology is revolutionizing the field of surgery, providing surgeons with the tools they need to improve precision, accuracy, and patient outcomes. As the company continues to lead the charge in this space, it’s clear that the future of surgery is bright. With a strong commitment to innovation and excellence, UltraGreen.ai is poised to continue driving the adoption of fluorescence-guided surgery and shaping the future of modern medicine.